BioXpress Overview

  • Year Founded
  • 2008

Year Founded

  • Status
  • Private

  • Employees
  • 3

Employees

  • Latest Deal Type
  • Early Stage VC

  • Investors
  • 6

BioXpress General Information

Description

Developer of biosimilar monoclonal antibodies (mAbs) designed to address situations like cancer, inflammation and autoimmunity. The company utilizes biosimilar biologic active pharmaceutical ingredients (APIs) to bring speed, efficiency and safety in developing biosimilar mAbs that impact patients' quality of life while maintaining low development costs, enabling doctors to make drugs accessible while also offering to prolong and improve the lives of patients across the globe.

Contact Information

Website
www.bioxpressbiosimilars.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • Campus Biotech Innovation Park
  • 15 Avenue de Secheron
  • 1202 Geneva
  • Switzerland
+41 022 000 00 00

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

BioXpress Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC Completed Startup
2. Accelerator/Incubator Completed Startup
1. Accelerator/Incubator Completed Startup
To view BioXpress’s complete valuation and funding history, request access »

BioXpress Executive Team (3)

Name Title Board Seat Contact Info
Luc-Alain Savoy Ph.D Co-Founder & Chairman
Igor Fisch Ph.D Co-Founder
You’re viewing 2 of 3 executive team members. Get the full list »

BioXpress Board Members (5)

Name Representing Role Since
Alexandra Richardson Ph.D Self Board Member 000 0000
Gerrit Hagens Ph.D Self Board Member 000 0000
Luc-Alain Savoy Ph.D BioXpress Co-Founder & Chairman 000 0000
You’re viewing 3 of 5 board members. Get the full list »

BioXpress Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

BioXpress Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
BioBac Angel Group Minority 000 0000 000000 0
EFI Lake Geneva Ventures Venture Capital Minority 000 0000 000000 0
EPFL Innovation Park Accelerator/Incubator Minority 000 0000 000000 0
Fongit Accelerator/Incubator Minority 000 0000 000000 0
Fongit Seed Invest Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 6 investors. Get the full list »

Ready to get started?

Request a free trial